Trials / Completed
CompletedNCT04340687
Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP
Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing Post-ERCP Pancreatitis in Patients With Difficult Cannulation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 664 (actual)
- Sponsor
- Air Force Military Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the two methods on preventing PEP are controversial. We hypothesized that some group of patients with difficult cannulation might benefit from the combination of indomethacin plus PDS (IP) compared with indomethacin alone (IN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Pancreatic duct stenting | A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2020-04-09
- Last updated
- 2020-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04340687. Inclusion in this directory is not an endorsement.